|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ަ����ѿ�� |
|
���� |
|
Ԥ�� |
| ��������������� | |
|
����� |
|
��ѧ�� |
| PubMed | |
|
Article by |
|
Article by |
ަ����ѿ�����ƺ�Ԥ���о���չ
�����, ��ѧ��
����ҽ�ƴ�ѧ��һ����ҽԺƤ���� �Ϸ� 230032
ަ����ѿ�Ľ��̡����ߵ����估����Ѫ��������ø��ˮƽ�뻼�ߵ�Ԥ���������.����������Ӧ��UVA��UVB���ơ��⻯ѧ�Ʒ���ע������ء�����2�������Ʒ��Ѿ��ɹ����ڸ���ަ����ѿ������.���õ����Ī˾͡��ѧ���ƶ�������ަ����ѿ����Ч�Ϻ�;�����ڽ�չ�ںͺ�Ƥ����ަ����ѿ��,ȫ��Ƥ�����������估�ͼ����Ļ�ѧҩ����װ����ʡ��ǻ��塢�����ᵪ��Ͱ�ù�ص�ϵͳӦ�ð�ȫ��Ч.������ʾ,Ӧ���ݲ�ͬ�IJ���ѡ�����˵��Ʒ�.
[2] Orenstein A, Haik J, Tamir J, et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg.2000,26(8): 765-769.
[3] Bisaccia E, Gonzalez J, Palangio M, et al. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. J Am Acad Dermatol,2000,43(2 Pt 1):263-271.
[4] Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol, 1999, 107(4): 707-711.
[5] Zane C, Leali C, Airo P,et al. "High-dose" UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J Am Acad Dermatol, 2001,44 (4): 629-633.
[6] Akaraphanth R, Douglass MC, Lim HW. et al. Hypopigmented mycosis fungoides: treatment and a 6(1/2)-year follow-up of 9 patients. J Am Acad Dermatol,2000, 42(1 Pt 1): 33-39.
[7] Maingon P, Truc G, Dalac S, et al. Radiotherapy of advanced mycosis fungoides: indications and results of total skin electron beam and photon beam irradiation. Radiother Oncol, 2000, 54(1): 73-78.
[8] Kirova YM, Piedbois Y, Haddad E, et al. Radiotherapy in the management of mycosis fungoides: indications, results, prognosis. Twenty years experience. Radiother Oncol, 1999,51(2): 147-151.
[9] Chinn DM, Chow S, Kim YH, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys, 1999,43(5): 951-958.
[10] Jones GW, Rosenthal D, Wilson LD. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer, 1999,85(9): 1985-1995.
[11] Abel EA. Skin neoplasias including cutaneous lymphoma, melanoma, and others: unapproved treatments or indications. Clin Dermatol, 2000, 18(2): 201-210.
[12] Au WY, Ng WM, Choy C, et al. Aggressive subcutaneous panniculitislike T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone. Br J Dermatol,2000, 143(2): 408-410.
[13] Coors EA, von den Driesch P. Treatment of erythrodermic cutaneous Tcell lymphoma with intermittent chlorambucil and lluocortolone therapy. Br J Dermatol,2000,143(1): 127-131.
[14] Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneons T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol,2000,42(1 Pt 1): 40-46.
[15] Jumbou O, N'Guyen JM, Tessier MH, et al. Long-term follow-up in 51patients with mycosis fungoides and Sezary syndrome treated by interferonalfa. Br J Dermatol, 1999,140(3): 427-431.
[16] Rupoli S, Barulli S, Guiducci B, et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multiecnter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. Haematologica, 1999,84(9): 809-813.
[17] Fritz TM, Kleinhans M, Nestle FO,et al. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sezary syndrome. Br J Dermatol, 1999,140(6): 1144-1147.
[18] Molina A, Nademanee A, Arber DA, et al. Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant, 1999,5 (6): 400-404.
[19] Diamandidou E, Colome M, Fayad L, et al.Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J Am Acad Dermatol, 1999,40(6 Pt 1): 914-924.
[20] Kim YH, Chow S, Varghese A, et al. Clinical characteristics and longterm outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol, 1999,135(1): 26-32.
[21] van Doom R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol, 2000, 136(4): 504-510.
[22] Heald PW, Glusac EJ. Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant. J Am Acad Dermatol, 2000,42(2 Pt 1):283-285.
[23] Zackheim HS. Cutaneous T cell lymphoma: update of treatment. Dermatology, 1999,199(2): 102-105.
[24] Bagot M, Boumsell L, Bensussan A. Contribution of immunotherapy to the treatment of T-cell lymphoma of the skin. Presse Med, 1999, 28 (34):1911-1916.